Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of multiple myeloma
• •Must have completed high-dose melphalan and autologous peripheral blood stem cell transplantation
• •* Transplant must have been completed 30-120 days ago
• •* Must not be receiving maintenance therapy
• •* Patients must have received 200 mg/m² of melphalan intravenously as a conditioning regimen (no dose reduction allowed)
• •No evidence of amyloidosis
• •No available donor
• •PATIENT CHARACTERISTICS:
• •ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%
• •Absolute neutrophil count \> 1,500/mm\^3
• •Platelet count \> 75,000/mm\^3
• •Bilirubin ≤ 1.5 times upper limit of normal
• •Transaminase ≤ 3 times upper limit of normal
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •Must have a negative HIV test
• •No baseline neurological disease \> grade I
• •No cranial nerve palsy
• •No demonstrated resistance to bortezomib
• •No history of allergic reactions attributed to bortezomib, boron, or mannitol
• •No cardiac arrhythmia
• •No unstable angina pectoris
• •No symptomatic congestive heart failure
• •No ongoing or active infection
• •No other uncontrolled illness
• •No psychiatric illness or social situations that would limit compliance with study requirements
• •PRIOR CONCURRENT THERAPY:
• •See Disease Characteristics
• •No other concurrent anticancer therapies or agents
• •No other concurrent investigational agents
• •Not receiving maintenance therapy after prior stem cell transplantation on another clinical trial